Elusys Therapeutics Inc. has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for use against a potential anthrax attack.   “Elusys is pleased to continue its successful track record of supplying a critical medicine to treat the deadly effects of anthrax exposure,” said Elizabeth Posillico, president and CEO of E...